Can dose intensification improve outcomes for intermediate- or high-risk prostate cancer?

For men with intermediate- or high-risk prostate cancer, standard radiation therapy delivers a uniform dose to the whole prostate. However, research shows that recurrences often happen at the original tumor site, suggesting that giving a higher radiation dose to the visible tumor (dose intensification) might improve cancer control. Several clinical trials are now testing this approach, aiming to boost the dose to the dominant lesion while possibly reducing dose to healthy tissue to limit side effects. Early results are promising, but the evidence is still evolving.

What the research says

Standard radiation therapy for prostate cancer has excellent outcomes, but dose escalation to the whole prostate increases late side effects ⁶¹⁰. Recurrence after radiation typically occurs at the site of the primary tumor, indicating that the dose to the dominant lesion is a key predictor of treatment failure ⁶¹⁰. This has led to the concept of tumor-focused radiation: intensifying the dose to the visible cancer while potentially de-intensifying dose to the rest of the prostate ⁶¹⁰.

The RadTARGET trial is a phase II randomized study directly comparing image-guided, tumor-focused radiation (with dose intensification to visible cancer and de-intensification to remaining prostate) versus standard radiation for intermediate- and high-risk prostate cancer. The primary goal is to show superior safety (fewer acute urinary or bowel side effects) while maintaining effectiveness ⁶¹⁰. Similarly, the SAFO trial is testing stereotactic ablative body radiotherapy (SABR) with a focal boost to the index lesion up to 50 Gy in 5 fractions, while sparing the bladder trigone and urethra ⁹. Both trials allow androgen deprivation therapy (ADT) as needed ⁹¹⁰.

Early data from the ARIEL trial show that after neoadjuvant ADT, visible prostate lesions shrink substantially (median 55.8%) and their MRI restriction spectrum imaging (RSI) signal decreases, suggesting a treatment response ⁴. MRI is increasingly used to identify the dominant tumor for dose intensification and to protect nearby structures like the urethra ¹¹. While these approaches are promising, the trials are ongoing, and results on long-term cancer control and side effects are not yet available ⁶⁹¹⁰.

What to ask your doctor

• Based on my MRI, is my dominant tumor visible and suitable for a focal radiation boost?
• Am I a candidate for a clinical trial like RadTARGET or SAFO that tests dose intensification?
• What are the potential benefits and risks of receiving a higher radiation dose to the tumor versus standard whole-prostate radiation?
• How would dose intensification affect my risk of urinary or bowel side effects?
• If I need ADT, how does that interact with a focal boost approach?